|Mr. David A. Ricks||Chairman, CEO & Pres||4.4M||N/A||1968|
|Dr. Daniel M. Skovronsky||Sr. VP, Chief Scientific Officer & Pres of Lilly Research Labs||2.14M||N/A||1973|
|Mr. Joshua L. Smiley||Exec. Officer||2.13M||N/A||1970|
|Ms. Anat Ashkenazi||Sr. VP & CFO||N/A||N/A||1973|
|Mr. Jacob S. Van Naarden||Chief Operating Officer of Loxo Oncology||N/A||N/A||1985|
|Mr. Donald A. Zakrowski||Chief Accounting Officer & VP of Fin.||N/A||N/A||N/A|
|Mr. Martin Bott MIBS||VP of Fin. & Special Projects||N/A||N/A||1963|
|Ms. Aarti Shreyas Shah Ph.D.||Sr. VP & Chief Information and Digital Officer||N/A||N/A||1964|
|Kevin Hern||VP of Investor Relations||N/A||N/A||N/A|
|Ms. Melissa Stapleton Barnes||Sr. VP of Enterprise Risk Management and Chief Ethics & Compliance Officer||N/A||N/A||1968|
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company primarily has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; and Junshi Biosciences. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Eli Lilly and Company’s ISS governance QualityScore as of 2 December 2020 is 9. The pillar scores are Audit: 1; Board: 10; Shareholder rights: 9; Compensation: 2.